Cybin Inc. Common Stock Market Cap ($233.50 Million)
Market Cap & Net Worth: Cybin Inc. Common Stock (HELP)
Cybin Inc. Common Stock market cap. Cybin Inc. Common Stock (NYSE MKT:HELP) has a market capitalization of $233.50 Million ($233.50 Million) as of November 5, 2026. Listed on the NYSE MKT stock exchange, this USA-based company holds position #15764 globally and #3763 in its home market, demonstrating a -7.51% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cybin Inc. Common Stock's stock price $4.68 by its total outstanding shares 49894131 (49.89 Million). Also see Cybin Inc. Common Stock (HELP) cash flow conversion for how efficiently the company converts equity into cash flow.
Cybin Inc. Common Stock Market Cap History (2026–2026)
Cybin Inc. Common Stock market cap history from 2026 to 2026. Data shows growth from $233.50 Million to $233.50 Million (0.00% CAGR). Check Cybin Inc. Common Stock stock quote for real-time trading data and today's change.
Cybin Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cybin Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is Cybin Inc. Common Stock growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of HELP by Market Capitalization
Companies near Cybin Inc. Common Stock in the global market cap rankings as of November 5, 2026. Also see HELP asset base for a full breakdown of the balance sheet.
Key companies related to Cybin Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Cybin Inc. Common Stock (2026–2026)
Market capitalization of Cybin Inc. Common Stock from 2026 to today. Between 2026 and today, Cybin Inc. Common Stock's market cap moved from $233.50 Million to $ 233.50 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $233.50 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Cybin Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $233.50 Million USD |
| MoneyControl | $233.50 Million USD |
| MarketWatch | $233.50 Million USD |
| marketcap.company | $233.50 Million USD |
| Reuters | $233.50 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cybin Inc. Common Stock
Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical tr… Read more